PHOENIX BIOTECH ACQUISITION CORP.

(PBAXU)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Phoenix Biotech Acquisition Corp. Class A Common Shares and Warrants to Commence Trading Separately on November 26, 2021

11/22/2021 | 04:15pm EDT

Oakland, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXU) (the “Company”), a blank-check company formed for the purpose of acquiring or merging with one or more businesses, today announced that the holders of the Company’s units may elect to separately trade the Class A common shares and warrants underlying the units commencing on November 26, 2021. Those units not separated will continue to trade on the NASDAQ Capital Market under the symbol “PBAXU” and the Class A common shares and warrants are expected to trade under the symbols “PBAX” and “PBAXW”, respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade.

A registration statement relating to the units and the underlying securities was declared effective by the Securities and Exchange Commission on October 5, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering was made by means of a prospectus, copies of which may be obtained by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 5th Floor, New York, New York 10022; Email: prospectus@cantor.com. Copies of the registration statement can be accessed for free through the SEC's website at www.sec.gov.

This press release contains statements that constitute “forward-looking statements,” including with respect to the initial public offering. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and prospectus for the offering filed with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this press release, except as required by law.

Contact Information:

Chris Ehrlich
chris@phoenixbiotechacquisitioncorp.com


Source: Phoenix Biotech Acquisition Corp.

2021 GlobeNewswire, Inc., source Press Releases

All news about PHOENIX BIOTECH ACQUISITION CORP.
05/13PHOENIX BIOTECH ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CO..
AQ
05/13Phoenix Biotech Acquisition Corp. Reports Earnings Results for the First Quarter Ended ..
CI
03/24PHOENIX BIOTECH ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CO..
AQ
03/24Phoenix Biotech Acquisition Corp. Reports Earnings Results for the Seven Months Ended D..
CI
2021PHOENIX BIOTECH ACQUISITION CORP.(NA : PBAX) added to NASDAQ Composite Index
CI
2021Phoenix Biotech Acquisition Corp. Class A Common Shares and Warrants to Commence Tradin..
AQ
2021PHOENIX BIOTECH ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CO..
AQ
2021PHOENIX BIOTECH ACQUISITION CORP. : Other Events, Financial Statements and Exhibits (form ..
AQ
2021PHOENIX BIOTECH ACQUISITION CORP. : Entry into a Material Definitive Agreement, Unregister..
AQ
2021PHOENIX BIOTECH ACQUISITION : Blank-Check Company Phoenix Biotech Acquisition Raises $175 ..
MT
More news
Financials (USD)
Sales
Net income
Net Debt
P/E ratio
Yield
Capitalization 230 M 230 M -
EV / Sales -1
EV / Sales 0
Nbr of Employees -
Free-Float 77,0%
Chart PHOENIX BIOTECH ACQUISITION CORP.
Duration : Period :
Phoenix Biotech Acquisition Corp. Technical Analysis Chart | PBAXU | US71902K2042 | MarketScreener
Technical analysis trends PHOENIX BIOTECH ACQUISITION CORP.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Managers and Directors
Christopher B. Ehrlich Chief Executive Officer & Director
Douglas Carl Fisher President
Daniel E. Geffken Chief Financial Officer
Brian G. Atwood Independent Director
Kathy D. LaPorte Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PHOENIX BIOTECH ACQUISITION CORP.-0.28%230
INVESTOR AB (PUBL)-18.02%57 686
CK HUTCHISON HOLDINGS LIMITED7.65%26 452
GROUPE BRUXELLES LAMBERT SA-13.63%13 259
HAL TRUST-7.68%12 522
AB INDUSTRIVÄRDEN (PUBL)-11.75%11 164